Pharma manufacturing news in brief
pharmafile | March 11, 2013 | News story | Business Services, Manufacturing and Production |Â Â Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent PharmaÂ
Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J recall.
Generic drugmaker Actavis has agreed to revise the terms of its 2010 injectable drug supply agreement with Sagent Pharmaceuticals, giving the latter an ‘enhanced profit split’ as well as rights to an additional product. Under the terms of the agreement Actavis manufactures a range of products for Sagent, which sell them in the US. Sagent now has rights to sell zoledronic acid 4mg injection, an osteoporosis treatment, and has agreed a modified termination date of 31 December, 2014, for the alliance, as well as a one-time termination fee of $5 million payable by Actavis.
Logistics specialist Marken has opened a new pharmaceutical depot in Beijing, China, with 850 sq. m. of Good Manufacturing Practice-compliant space for temperature controlled storage and distribution of clinical trial supplies. The new depot is located in the same unit as Marken’s Beijing branch office and provides temperature controlled storage and distribution for pharmaceuticals, biologics, medical devices and diagnostic equipment. Marken also operates pharma depots in Germany, the US, Singapore, Argentina and Mexico.
DSM has signed a three-year supply agreement with Eisai for the production of the latter’s late-stage breast cancer drug Halaven (eribulin mesylate) and a range of other sterile developmental compounds in the US. Under the terms of the deal DSM will supply eribulin mesylate for the US market from its facility in Greenville, North Carolina. Financial terms of the deal have not been disclosed.
Johnson & Johnson has been forced to issue yet another recall for its McNeil Consumer Healthcare unit, this time affecting three products in its K-Y Jelly personal lubricant range. The company has also decided to take the brands off the market because they may require formal approval by the FDA, despite having been sold under medical device regulations for years.
SAFC is expanding its production facility in Irvine, Scotland, to support large-scale production of bulk dry power media and reagents used in biopharmaceutical manufacturing. The expansion will lead to ‘redundant’ capacity at SAFC’s existing dry powder media facility in Lenexa, Kansas, US. SAFC said it will construct a purpose-built Animal Component Free (ACF) dry powder media manufacturing facility to complement the existing liquid cell culture media, buffers and reagents capabilities in Irvine. Ground breaking for the new facility is expected to commence this month and it is due to come online in the first quarter of 2014.
Phil Taylor
Related Content
J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …
